MAIA Biotechnology, Inc. SEC filings MAIA
MAIA Biotechnology, Inc. has 503 filings in SEC EDGAR's recent list, going back to Oct 15, 2021. Its latest annual report, Form ARS, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 6, 2026 | — |
| EFFECT | Filing | Aug 28, 2026 | — |
| D | Filing | Jan 5, 2026 | — |
| D | Filing | Oct 14, 2025 | — |
| D | Filing | Jun 11, 2025 | — |
| D | Filing | Mar 4, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2025 | — |
| D | Filing | Nov 12, 2024 | — |
| D | Filing | Mar 21, 2024 | — |
| D | Filing | Nov 29, 2023 | — |
| EFFECT | Filing | Aug 23, 2023 | — |
| CORRESP | Letter to the SEC | Aug 21, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2023 | — |
| RW | Filing | Jul 18, 2023 | — |
| DRS | Filing | Jun 1, 2023 | — |
| EFFECT | Filing | Apr 24, 2023 | — |
| CORRESP | Letter to the SEC | Apr 21, 2023 | — |
| CORRESP | Letter to the SEC | Apr 21, 2023 | — |
| CORRESP | Letter to the SEC | Apr 21, 2023 | — |
| CORRESP | Letter to the SEC | Apr 21, 2023 | — |
| CORRESP | Letter to the SEC | Apr 18, 2023 | — |
| CORRESP | Letter to the SEC | Apr 18, 2023 | — |
| CORRESP | Letter to the SEC | Feb 13, 2023 | — |
| CORRESP | Letter to the SEC | Feb 13, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 7, 2023 | — |
| CORRESP | Letter to the SEC | Feb 7, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2022 | — |
| DRS | Filing | Dec 23, 2022 | — |
| SEC STAFF LETTER | Filing | Jul 27, 2022 | — |
| EFFECT | Filing | Jul 27, 2022 | — |
| CERT | Nyse american certification | Jul 27, 2022 | — |
| 8-A12B | Filing | Jul 27, 2022 | — |
| CORRESP | Letter to the SEC | Jul 25, 2022 | — |
| CORRESP | Letter to the SEC | Jul 25, 2022 | — |
| CORRESP | Letter to the SEC | Jul 21, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2022 | — |
| CORRESP | Letter to the SEC | Jul 20, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2022 | — |
| CORRESP | Letter to the SEC | Jun 28, 2022 | — |
| CORRESP | Letter to the SEC | Jun 28, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2022 | — |
| CORRESP | Letter to the SEC | May 31, 2022 | — |
| UPLOAD | Letter from the SEC | May 23, 2022 | — |
| CORRESP | Letter to the SEC | Apr 29, 2022 | — |
| SEC STAFF LETTER | Filing | Apr 25, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2022 | — |
| CORRESP | Letter to the SEC | Apr 11, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2022 | — |
| DRSLTR | Filing | Feb 14, 2022 | — |
| DRS/A | Filing | Feb 14, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2022 | — |
| DRSLTR | Filing | Dec 22, 2021 | — |
| DRS/A | Filing | Dec 22, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2021 | — |
| DRS | Filing | Oct 15, 2021 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MAIA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1878313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.